Company intelligence / Profile preview

Koda Therapeutics

Ownership: Private
Development stage: Other

Overview

CoDa Therapeutics' lead candidate Nexagon has demonstrated safety and tolerability in over 380 wounds across more than 180 subjects in multiple Phase 1/2 studies for wound healing. Clinical data show improved wound closure rates, reduced inflammation, swelling, scarring, and lesion spread. The technology has broad preclinical efficacy across various tissues including skin, eye, brain, nerve, and spinal cord.

Therapeutic areas: NeurologyDermatologyOphthalmologyOtherImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

RUSNANO: Investment partnership for Russian market access/licensing of Nexagon

Beyond the preview

Go deeper on Koda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koda Therapeutics.

Explore the full profile